Controlled pulmonary drug and gene delivery using polymeric nano-carriers

Journal of Controlled Release

Volumn 161, Issue 2, 2012, Pages 214-224

  Beck Broichsitter, Moritz ^a   Merkel, Olivia M ^a,b   Kissel, Thomas ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Gene therapy; Inhalation; Isolated lung model; Nanoparticles; Pulmonary drug delivery

Indexed keywords

CARRIER VEHICLES; CONTROLLED DELIVERY; EX-VIVO; GENE DELIVERY; IN-VIVO; INHALATION; LUNG MODEL; NANO-SIZED PARTICLES; NANOCARRIERS; NOVEL CONCEPT; PHARMACOLOGICAL EFFECTS; POLYMERIC NANOPARTICLES; PULMONARY ABSORPTION; PULMONARY DELIVERY; PULMONARY DRUG; PULMONARY DRUG DELIVERY; RESPIRATORY TRACT; SOLID BASIS; SYSTEMIC THERAPY; THERAPEUTIC TOOLS;

BIOLOGICAL ORGANS; DRUG THERAPY; GENE THERAPY; GENE TRANSFER; NANOPARTICLES; PARTICLE SIZE;

POLYMERS;

CD31 ANTIGEN; DORNASE ALFA; DOXORUBICIN; DRUG CARRIER; GUAIFENESIN; INSULIN; NANOPARTICLE; PHARMACEUTICAL VEHICLES AND ADDITIVES; POLYGLYCOLIDE; POLYLACTIDE; POLYMER; POLYSTYRENE; POLYVINYL ALCOHOL; SALBUTAMOL; SURFACTANT; VIRUS VECTOR;

AEROSOL; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFOCAL LASER MICROSCOPY; CONTROLLED DRUG RELEASE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RETENTION; DRUG SOLUTION; GENE DELIVERY SYSTEM; GENE TARGETING; HUMAN; IN VITRO STUDY; IN VIVO GENE TRANSFER; LUNG; MEDICAL RESEARCH; MODEL; NANOENCAPSULATION; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY FUNCTION; RESPIRATORY SYSTEM; REVIEW; SPRAY DRYING;

ANIMALS; DRUG CARRIERS; GENE TRANSFER TECHNIQUES; HUMANS; LUNG; LUNG DISEASES; NANOPARTICLES; POLYMERS;

EID: 84862668679     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.12.004     Document Type: Review

References (141)

1. H.M. Courrier, N. Butz, T.F. Vandamme, Pulmonary drug delivery systems: recent developments and prospects, Crit. Rev. Ther. Drug Carrier Syst. 19 (2002) 425-498.
2. D.A. Groneberg, C. Witt, U. Wagner, K.F. Chung, A. Fischer, Fundamentals of pulmonary drug delivery, Respir. Med. 97 (2003) 382-387.
3. J.S. Patton, P.R. Byron, Inhaling medicines: delivering drugs to the body through the lungs, Nat. Rev. Drug Discov. 6 (2007) 67-74.
4. J. Hukkanen, O. Pelkonen, J. Hakkola, H. Raunio, Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung, Crit. Rev. Toxicol. 32 (2002) 391-411.
5. C.P. van der Schans, Bronchial mucus transport, Respir. Care 52 (2007) 1150-1158.
6. M. Geiser, Update on macrophage clearance of inhaled micro- and nanoparticles, J. Aerosol Med. 23 (2010) 207-217.
7. T. Gessler, W. Seeger, T. Schmehl, Inhaled prostanoids in the therapy of pulmonary hypertension, J. Aerosol Med. 21 (2008) 1-12.
8. B.D. Kurmi, J. Kayat, V. Gajbhiye, R.K. Tekade, N.K. Jain, Micro- and nanocarrier-mediated lung targeting, Expert Opin. Drug Deliv. 7 (2010) 781-794.
9. A.H.L. Chow, H.H.Y. Tong, P. Chattopadhyay, B.Y. Shekunov, Particle engineering for pulmonary drug delivery, Pharm. Res. 24 (2007) 411-437.
10. J.C. Sung, B.L. Pulliam, D.A. Edwards, Nanoparticles for drug delivery to the lungs, Trends Biotechnol. 25 (2007) 563-570.
11. S. Azarmi, W.H. Roa, R. Loebenberg, Targeted delivery of nanoparticles for the treatment of lung diseases, Adv. Drug Deliv. Rev. 60 (2008) 863-875.
12. E. Rytting, J. Nguyen, X. Wang, T. Kissel, Biodegradable polymeric nanocarriers for pulmonary drug delivery, Expert Opin. Drug Deliv. 5 (2008) 629-639.
13. W. Yang, J.I. Peters, R.O. Williams III, Inhaled nanoparticles-a current review, Int. J. Pharm. 356 (2008) 239-247.
14. T. Lebhardt, S. Roesler, M. Beck-Broichsitter, T. Kissel, Polymeric nanocarriers for drug delivery to the lung, J. Drug Deliv. Sci. Technol. 20 (2010) 171-180.
15. I. Roy, N. Vij, Nanodelivery in airway diseases: challenges and therapeutic applications, Nanomedicine: NBM 6 (2010) 237-244.
16. C. Mobley, G. Hochhaus, Methods used to assess pulmonary deposition and absorption of drugs, Drug Discov. Today 6 (2001) 367-375.
17. M. Sakagami, In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery, Adv. Drug Deliv. Rev. 58 (2006) 1030-1060.
18. C.A. Fernandes, R. Vanbever, Preclinical models for pulmonary drug delivery, Expert Opin. Drug Deliv. 6 (2009) 1231-1245.
19. R.U. Agu, M.I. Ugwoke, In vitro and in vivo testing methods for respiratory drug delivery, Expert Opin. Drug Deliv. 8 (2011) 57-69.
20. M. Beck-Broichsitter, T. Schmehl, W. Seeger, T. Gessler, Evaluating the controlled release properties of inhaled nanoparticles using isolated, perfused, and ventilated lung models, J. Nanomaterials (2011) Article ID 163791.
21. S.A. Cryan, N. Sivadas, L. Garcia-Contreras, In vivo animal models for drug delivery across the lung mucosal barrier, Adv. Drug Deliv. Rev. 59 (2007) 1133-1151.
22. J. Yu, Y.W. Chien, Pulmonary drug delivery: physiologic and mechanistic aspects, Crit. Rev. Ther. Drug Carrier Syst. 14 (1997) 395-453.
23. S.K. Lai, Y.-Y. Wang, D. Wirtz, J. Hanes, Micro- and macrorheology of mucus, Adv. Drug Deliv. Rev. 61 (2009) 86-100.
24. S.K. Lai, Y.Y. Wang, J. Hanes, Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues, Adv. Drug Deliv. Rev. 61 (2009) 158-171.
25. L.A.J.M. Creuwels, L.M.G. van Golde, H.P. Haagsman, The pulmonary surfactant system: biochemical and clinical aspects, Lung 175 (1997) 1-39.
26. H. Fehrenbach, Alveolar epithelial type II cell: defender of the alveolus revisited, Respir. Res. 2 (2001) 33-46.
27. J.D. Brain, Mechanisms, measurement, and significance of lung macrophage function, Environ. Health Perspect. 97 (1992) 5-10.
28. H. Olschewski, G. Simonneau, N. Galie, T. Higenbottam, R. Naeije, L.J. Rubin, S. Nikkho, R. Speich, M.M. Hoeper, J. Behr, J. Winkler, O. Sitbon, W. Popov, H.A. Ghofrani, A. Manes, D.G. Kiely, R. Ewert, A. Meyer, P.A. Corris, M. Delcroix, M. Gomez-Sanchez, H. Siedentop, W. Seeger, Inhaled iloprost for severe pulmonary hypertension, N. Engl. J. Med. 347 (2002) 322-329.
29. R. Langer, New methods of drug delivery, Science 249 (1990) 1527-1533.
30. P.G.A. Rogueda, D. Traini, The nanoscale in pulmonary delivery. Part 2: Formulation platforms, Expert Opin. Drug Deliv. 4 (2007) 607-620.
31. K.S. Soppimath, T.M. Aminabhavi, A.R. Kulkarni, W.E. Rudzinski, Biodegradable polymeric nanoparticles as drug delivery devices, J. Control. Release 70 (2001) 1-20.
32. M. Beck-Broichsitter, J. Gauss, C.B. Packhaeuser, K. Lahnstein, T. Schmehl, W. Seeger, T. Kissel, T. Gessler, Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model, Int. J. Pharm. 367 (2009) 169-178.
33. J.C. Sung, D.J. Padilla, L. Garcia-Contreras, J.L. VerBerkmoes, D. Durbin, C.A. Peloquin, K.J. Elbert, A.J. Hickey, D.A. Edwards, Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery, Pharm. Res. 26 (2009) 1847-1855.
34. M. Beck-Broichsitter, J. Gauss, T. Gessler, W. Seeger, T. Kissel, T. Schmehl, Pulmonary targeting with biodegradable salbutamol-loaded nanoparticles, J. Aerosol Med. 23 (2010) 47-57.
35. E. Rytting, M. Bur, R. Cartier, T. Bouyssou, X.Wang, M. Krueger, C.M. Lehr, T. Kissel, In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles, J. Control. Release 141 (2010) 101-107.
36. W.H. Roa, S. Azarmi,M.H.D.K. Al-Hallak,W.H. Finlay, A.M.Magliocco, R. Loebenberg, Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model, J. Control. Release 150 (2011) 49-55.
37. C. Vauthier, K. Bouchemal, Methods for the preparation and manufacture of polymeric nanoparticles, Pharm. Res. 26 (2009) 1025-1058.
38. T. Jung, A. Breitenbach, T. Kissel, Sulfobutylated poly(vinyl alcohol)-graftpoly( lactide-co-glycolide)s facilitate the preparation of small negatively charged biodegradable nanospheres, J. Control. Release 67 (2000) 157-169.
39. M. Beck-Broichsitter, E. Rytting, T. Lebhardt, X. Wang, T. Kissel, Preparation of nanoparticles by solvent displacement for drug delivery: A shift in the "ouzo region" upon drug loading, Eur. J. Pharm. Sci. 41 (2010) 244-253.
40. L. Peltonen, H. Valo, R. Kolakovic, T. Laaksonen, J. Hirvonen, Electrospraying, spray drying and related techniques for production and formulation of drug nanoparticles, Expert Opin. Drug Deliv. 7 (2010) 705-719.
41. R. Vehring, Pharmaceutical particle engineering via spray drying, Pharm. Res. 25 (2008) 999-1022.
42. P.C. Seville, H.Y. Li, T.P. Learoyd, Spray-dried powders for pulmonary drug delivery, Crit. Rev. Ther. Drug Carrier Syst. 24 (2007) 307-360.
43. A. Jaworek, Micro- and nanoparticle production by electrospraying, Powder Technol. 176 (2007) 18-35.
44. X. Li, N. Anton, C. Arpagaus, F. Belleteix, T.F. Vandamme, Nanoparticles by spray drying using innovative new technology: the Buechi Nano Spray Dryer B-90, J. Control. Release 147 (2010) 304-310.
45. K. Buerki, I. Jeon, C. Arpagaus, G. Betz, New insights into respirable protein powder preparation using a nano spray dryer, Int. J. Pharm. 408 (2011) 248-256.
46. S.H. Lee, D. Heng, W.K. Ng, H.K. Chan, R.B.H. Tan, Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy, Int. J. Pharm. 403 (2011) 192-200.
47. M. Beck-Broichsitter, C. Schweiger, T. Schmehl, T. Gessler,W. Seeger, T. Kissel, Characterization of novel spray-dried polymeric particles for controlled pulmonary drug delivery, J. Control. Release (2011), doi:10.1016/j.jconrel. 2011.1010.1030.
48. G. Pilcer, K. Amighi, Formulation strategy and use of excipients in pulmonary drug delivery, Int. J. Pharm. 392 (2010) 1-19.
49. J.M. Anderson, M.S. Shive, Biodegradation and biocompatibility of PLA and PLGA microspheres, Adv. Drug Deliv. Rev. 28 (1997) 5-24.
50. I. Bala, S. Hariharan, M.N.V.R. Kumar, PLGA nanoparticles in drug delivery: the state of the art, Crit. Rev. Ther. Drug Carrier Syst. 21 (2004) 387-422.
51. C.E. Astete, C.M. Sabliov, Synthesis and characterization of PLGA nanoparticles, J. Biomater. Sci. Polym. Ed. 17 (2006) 247-289.
52. L.A. Dailey, T. Kissel, New poly(lactic-co-glycolic acid) derivatives: modular polymers with tailored properties, Drug Discov. Today: Technol. 2 (2005) 7-14.
53. L.A. Dailey, M. Wittmar, T. Kissel, The role of branched polyesters and their modifications in the development of modern drug delivery vehicles, J. Control. Release 101 (2005) 137-149.
54. J.M. Barichello, M. Morishita, K. Takayama, T. Nagai, Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method, Drug Dev. Ind. Pharm. 25 (1999) 471-476.
55. K. Pancholi, E. Stride, M. Edirisinghe, In vitro method to characterize diffusion of dye from polymeric particles: a model for drug release, Langmuir 25 (2009) 10007-10013.
56. H. Seyednejad, A.H. Ghassemi, C.F. van Nostrum, T. Vermonden, W.E. Hennink, Functional aliphatic polyesters for biomedical and pharmaceutical applications, J. Control. Release 152 (2011) 168-176.
57. A. Breitenbach, T. Jung, W. Kamm, T. Kissel, Biodegradable comb polyesters containing polyelectrolyte backbones facilitate the preparation of nanoparticles with defined surface structure and bioadhesive properties, Polym. Adv. Technol. 13 (2002) 938-950.
58. M. Wittmar, F. Unger, T. Kissel, Biodegradable brushlike branched polyesters containing a charge-modified poly(vinyl alcohol) backbone as a platform for drug delivery systems: synthesis and characterization, Macromolecules 39 (2006) 1417-1424.
59. X. Wang, X. Xie, C. Cai, E. Rytting, T. Steele, T. Kissel, Biodegradable branched polyesters poly(vinyl sulfonate-co-vinyl alcohol)-graft-poly(D, L-lactic-co-glycolic acid) as a negatively charged polyelectrolyte platform for drug delivery: Synthesis and characterization, Macromolecules 41 (2008) 2791-2799.
60. J. Nguyen, T.W.J. Steele, O. Merkel, R. Reul, T. Kissel, Fast degrading polyesters as siRNA nano-carriers for pulmonary gene therapy, J. Control. Release 132 (2008) 243-251.
61. F. Unger, M. Wittmar, F. Morell, T. Kissel, Branched polyesters based on poly [vinyl-3-(dialkylamino)alkylcarbamate-co-vinyl acetate-co-vinyl alcohol]-graft-poly(D, L-lactide-co-glycolide): effects of polymer structure on in vitro degradation behaviour, Biomaterials 29 (2008) 2007-2014.
62. L.A. Dailey, E. Kleemann, M. Wittmar, T. Gessler, T. Schmehl, C. Roberts, W. Seeger, T. Kissel, Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA, Pharm. Res. 20 (2003) 2011-2020.
63. F. Unger, M. Wittmar, T. Kissel, Branched polyesters based on poly[vinyl- 3-(dialkylamino)alkylcarbamate-co-vinyl acetate-co-vinyl alcohol]-graftpoly( D, L-lactide-co-glycolide): effects of polymer structure on cytotoxicity, Biomaterials 28 (2007) 1610-1619.
64. L.A. Dailey, N. Jekel, L. Fink, T. Gessler, T. Schmehl, M. Wittmar, T. Kissel,W. Seeger, Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung, Toxicol. Appl. Pharmacol. 215 (2006) 100-108.
65. J. Nguyen, R. Reul, T. Betz, E. Dayyoub, T. Schmehl, T. Gessler, U. Bakowsky, W. Seeger, T. Kissel, Nanocomposites of lung surfactant and biodegradable cationic nanoparticles improve transfection efficiency to lung cells, J. Control. Release 140 (2009) 47-54.
66. J. Fiegel, J. Fu, J. Hanes, Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs, J. Control. Release 96 (2004) 411-423.
67. V.F. Fiore, M.C. Lofton, S. Roser-Page, S.C. Yang, J. Roman, N. Murthy, T.H. Barker, Polyketal microparticles for therapeutic delivery to the lung, Biomaterials 31 (2011) 810-817.
68. S. Gill, R. Loebenberg, T. Ku, S. Azarmi, W. Roa, E.J. Prenner, Nanoparticles: characteristics, mechanisms of action, and toxicity in pulmonary drug delivery - a review, J. Biomed. Nanotechnol. 3 (2007) 107-119.
69. J.W. Card, D.C. Zeldin, J.C. Bonner, E.R. Nestmann, Pulmonary applications and toxicity of engineered nanoparticles, Am. J. Physiol. 295 (2008) L400-L411.
70. W.H. De Jong, P.J.A. Borm, Drug delivery and nanoparticles: applications and hazards, Int. J. Nanomed. 3 (2008) 133-149.
71. A. Nemmar, M.F. Hoylaerts, P.H.M. Hoet, J. Vermylen, B. Nemery, Size effect of intratracheally instilled particles on pulmonary inflammation and vascular thrombosis, Toxicol. Appl. Pharmacol. 186 (2003) 38-45.
72. O. Harush-Frenkel, M. Bivas-Benita, T. Nassar, C. Springer, Y. Sherman, A. Avital, Y. Altschuler, J. Borlak, S. Benita, A safety and tolerability study of differentlycharged nanoparticles for local pulmonary drug delivery, Toxicol. Appl. Pharmacol. 246 (2010) 83-90.
73. R.H. Müller, S. Gohla, C.M. Keck, State of the art of nanocrystals - special features, production, nanotoxicology aspects and intracellular delivery, Eur. J. Pharm. Biopharm. 78 (2011) 1-9.
74. M. Beck-Broichsitter, C. Ruppert, T. Schmehl, A. Guenther, T. Betz, U. Bakowsky, W. Seeger, T. Kissel, T. Gessler, Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro, Nanomedicine: NBM 7 (2011) 341-350.
75. A. Nemmar, J. Hamoir, B. Nemery, P. Gustin, Evaluation of particle translocation across the alveolo-capillary barrier in isolated perfused rabbit lung model, Toxicology 208 (2005) 105-113.
76. K. Sarlo, K.L. Blackburn, E.D. Clark, J. Grothaus, J. Chaney, S. Neu, J. Flood, D. Abbott, C. Bohne, K. Casey, C. Fryer, M. Kuhn, Tissue distribution of 20 nm, 100 nm and 1000 nm fluorescent polystyrene latex nanospheres following acute systemic or acute and repeat airway exposure in the rat, Toxicology 263 (2009) 117-126.
77. I.M. El-Sherbiny, D.G. Villanueva, D. Herrera, H.D.C. Smyth, Overcoming lung clearance mechanisms for controlled release drug delivery, in: H.D.C. Smyth, A.J. Hickey (Eds.), Controlled Pulmonary Drug Delivery, Springer, New York, 2011, pp. 101-126.
78. J. Heyder, Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery, Proc. Am. Thorac. Soc. 1 (2004) 315-320.
79. T.C. Carvalho, J.I. Peters, R.O. Williams III, Influence of particle size on regional lung deposition: what evidence is there? Int. J. Pharm. 406 (2011) 1-10.
80. J. Heyder, J. Gebhart, G. Rudolf, C.F. Schiller, W. Stahlhofen, Deposition of particles in the human respiratory tract in the size range 0.005-15 μm, J. Aerosol Sci. 17 (1986) 811-825.
81. C.F. Schiller, J. Gebhardt, J. Heyder, G. Rudolf, W. Stahlhofen, Deposition of monodisperse insoluble aerosol particles in the 0.005 to 0.2 μm size range within the human respiratory tract, Ann. Occup. Hyg. 32 (1988) 41-49.
82. K. Edsman, H. Haegerstroem, Pharmaceutical applications of mucoadhesion for the non-oral routes, J. Pharm. Pharmacol. 57 (2005) 3-22.
83. A. Henning, M. Schneider, N. Nafee, L. Muijs, E. Rytting, X. Wang, T. Kissel, D. Grafahrend, D. Klee, C.M. Lehr, Influence of particle size and material properties on mucociliary clearance from the airways, J. Aerosol Med. 23 (2010) 233-241.
84. D.A. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A. Ben-Jebria, M.L. Eskew, J. Mintzes, D. Deaver, N. Lotan, R. Langer, Large porous particles for pulmonary drug delivery, Science 276 (1997) 1868-1871.
85. I.M. El-Sherbiny, S. McGill, H.D.C. Smyth, Swellable microparticles as carriers for sustained pulmonary drug delivery, J. Pharm. Sci. 99 (2010) 2343-2356.
86. L.A. Dailey, T. Schmehl, T. Gessler, M. Wittmar, F. Grimminger, W. Seeger, T. Kissel, Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features, J. Control. Release 86 (2003) 131-144.
87. N. Tsapis, D. Bennett, B. Jackson, D.A. Weitz, D.A. Edwards, Trojan particles: large porous carriers of nanoparticles for drug delivery, Proc. Natl. Acad. Sci. 99 (2002) 12001-12005.
88. T. Lebhardt, S. Roesler, H.P. Uusitalo, T. Kissel, Surfactant-free redispersible nanoparticles in fast-dissolving composite microcarriers for dry-powder inhalation, Eur. J. Pharm. Biopharm. 78 (2011) 90-96.
89. A. Steimer, E. Haltner, C.M. Lehr, Cell culture models of the respiratory tract relevant to pulmonary drug delivery, J. Aerosol Med. 18 (2005) 137-182.
90. M. Bur, C.M. Lehr, Pulmonary cell culture models to study the safety and efficacy of innovative aerosol medicines, Expert Opin. Drug Deliv. 5 (2008) 641-652.
91. P. Gerde, Animal models and their limitations: on the problem of high-to-low dose extrapolations following inhalation exposures, Exp. Toxicol. Pathol. 57 (2005) 143-146.
92. J.S. Patton, Mechanisms of macromolecule absorption by the lungs, Adv. Drug Deliv. Rev. 19 (1996) 3-36.
93. B.M. Kinsey, C.L. Densmore, F.M. Orson, Non-viral gene delivery to the lungs, Curr. Gene Ther. 5 (2005) 181-194.
94. U. Griesenbach, D.M. Geddes, E.W.F.W. Alton, Gene therapy progress and prospects: cystic fibrosis, Gene Ther. 13 (2006) 1061-1067.
95. M.K. Aneja, J.P. Geiger, A. Himmel, C. Rudolph, Targeted gene delivery to the lung, Expert Opin. Drug Deliv. 6 (2009) 567-583.
96. N. Sanders, C. Rudolph, K. Braeckmans, S.C. De Smedt, J. Demeester, Extracellular barriers in respiratory gene therapy, Adv. Drug Deliv. Rev. 61 (2009) 115-127.
97. O.M. Merkel, M. Zheng, H. Debus, T. Kissel, Pulmonary gene delivery using polymeric non-viral vectors, Bioconjug. Chem. (2011), doi:10.1021/bc200296q.
98. O.M. Merkel, T. Kissel, Nonviral pulmonary delivery of siRNA, Acc. Chem. Res. (2011), doi:10.1021/ar200110p.
99. S. Li, L. Huang, Nonviral gene therapy: promises and challenges, Gene Ther. 7 (2000) 31-34.
100. T. Merdan, J. Callahan, H. Petersen, K. Kunath, U. Bakowsky, P. Kopeckova, T. Kissel, J. Kopecek, Pegylated polyethylenimine-Fab' antibody fragment conjugates for targeted gene delivery to human ovarian carcinoma cells, Bioconjug. Chem. 14 (2003) 989-996.
101. M. Koping-Hoggard, I. Tubulekas, H. Guan, K. Edwards, M. Nilsson, K.M. Varum, P. Artursson, Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo, Gene Ther. 8 (2001) 1108-1121.
102. C. Rudolph, J. Lausier, S. Naundorf, R.H. Mueller, J. Rosenecker, In vivo gene delivery to the lung using polyethylenimine and fractured polyamidoamine dendrimers, J. Gene Med. 2 (2000) 269-278.
103. M. Bivas-Benita, M.Y. Lin, S.M. Bal, K.E. van Meijgaarden, K.L.M.C. Franken, A.H. Friggen, H.E. Junginger, G. Borchard,M.R. Klein, T.H.M. Ottenhoff, Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice, Vaccine 27 (2009) 4010-4017.
104. D. Fischer, T. Bieber, Y. Li, H.P. Elsasser, T. Kissel, A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity, Pharm. Res. 16 (1999) 1273-1279.
105. H. Petersen, T. Merdan, K. Kunath, D. Fischer, T. Kissel, Poly(ethylenimine-co-Llactamide-co-succinamide): a biodegradable polyethylenimine derivative with an advantageous pH-dependent hydrolytic degradation for gene delivery, Bioconjug. Chem. 13 (2002) 812-821.
106. A. Beyerle, O. Merkel, T. Stoeger, T. Kissel, PEGylation affects cytotoxicity and cell-compatibility of poly(ethylene imine) for lung application: structure-function relationships, Toxicol. Appl. Pharmacol. 242 (2010) 146-154.
107. E. Kleemann, N. Jekel, L.A. Dailey, S. Roesler, L. Fink, N. Weissmann, R. Schermuly, T. Gessler, T. Schmehl, C.J. Roberts, W. Seeger, T. Kissel, Enhanced gene expression and reduced toxicity in mice using polyplexes of low-molecular-weight poly(ethylene imine) for pulmonary gene delivery, J. Drug Target. 17 (2009) 638-651.
108. C. Rudolph, U. Schillinger, C. Plank, A. Gessner, P. Nicklaus, R.H. Mueller, J. Rosenecker, Nonviral gene delivery to the lung with copolymer-protected and transferrin-modified polyethylenimine, Biochim. Biophys. Acta 1573 (2002) 75-83.
109. E. Vives, P. Brodin, B. Lebleu, A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus, J. Biol. Chem. 272 (1997) 16010-16017.
110. E. Kleemann, M. Neu, N. Jekel, L. Fink, T. Schmehl, T. Gessler, W. Seeger, T. Kissel, Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI, J. Control. Release 109 (2005) 299-316.
111. S. Mao, M. Neu, O. Germershaus, O. Merkel, J. Sitterberg, U. Bakowsky, T. Kissel, Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)-graft-poly(ethylene glycol) block copolymer/SiRNA polyplexes, Bioconjug. Chem. 17 (2006) 1209-1218.
112. O.M. Merkel, A. Beyerle, D. Librizzi, A. Pfestroff, M. Behr Thomas, B. Sproat, J. Barth Peter, T. Kissel, Nonviral siRNA delivery to the lung: investigation of PEG-PEI polyplexes and their in vivo performance, Mol. Pharm. 6 (2009) 1246-1260.
113. A. Beyerle, A. Braun, O. Merkel, F. Koch, T. Kissel, T. Stoeger, Comparative in vivo study of poly(ethylene imine)/siRNA complexes for pulmonary delivery in mice, J. Control. Release 151 (2011) 51-56.
114. O.M. Merkel, R. Urbanics, P. Bedocs, Z. Rozsnyay, L. Rosivall, M. Toth, T. Kissel, J. Szebeni, In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine- graftpoly( ethylene glycol) block copolymers, Biomaterials 32 (2011) 4936-4942.
115. O.M. Merkel, A. Beyerle, B.M. Beckmann, M. Zheng, R.K. Hartmann, T. Stoeger, T. Kissel, Polymer-related off-target effects in non-viral siRNA delivery, Biomaterials 32 (2011) 2388-2398.
116. M. Bivas-Benita, S. Romeijn, H.E. Junginger, G. Borchard, PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium, Eur. J. Pharm. Biopharm. 58 (2004) 1-6.
117. M. Wittmar, J.S. Ellis, F. Morell, F. Unger, J.C. Schumacher, C.J. Roberts, S.J.B. Tendler, M.C. Davies, T. Kissel, Biophysical and transfection studies of an amine-modified poly(vinyl alcohol) for gene delivery, Bioconjug. Chem. 16 (2005) 1390-1398.
118. W. Zhang, H. Yang, X. Kong, S. Mohapatra, H.S. Juan-Vergara, G. Hellermann, S. Behera, R. Singam, R.F. Lockey, S.S. Mohapatra, Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene, Nat. Med. 11 (2005) 56-62.
119. X. Kong, W. Zhang, R.F. Lockey, A. Auais, G. Piedimonte, S.S. Mohapatra, Respiratory syncytial virus infection in Fischer 344 rats is attenuated by short interfering RNA against the RSV-NS1 gene, Genet. Vaccines Ther. 5 (2007) 4.
120. K.A. Howard, U.L. Rahbek, X. Liu, C.K. Damgaard, S.Z. Glud, M.O. Andersen, M.B. Hovgaard, A. Schmitz, J.R. Nyengaard, F. Besenbacher, J. Kjems, RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system, Mol. Ther. 14 (2006) 476-484.
121. S.Z. Glud, J.B. Bramsen, F. Dagnaes-Hansen, J. Wengel, K.A. Howard, J.R. Nyengaard, J. Kjems, Naked siLNA-mediated gene silencing of lung bronchoepithelium EGFP expression after intravenous administration, Oligonucleotides 19 (2009) 163-168.
122. E.J.B. Nielsen, J.M. Nielsen, D. Becker, A. Karlas, H. Prakash, S.Z. Glud, J. Merrison, F. Besenbacher, T.F. Meyer, J. Kjems, K.A. Howard, Pulmonary gene silencing in transgenic EGFP mice using aerosolised chitosan/siRNA nanoparticles, Pharm. Res. 27 (2010) 2520-2527.
123. J. Chen, X. Gao, K. Hu, Z. Pang, J. Cai, J. Li, H. Wu, X. Jiang, Galactose-poly(ethylene glycol)-polyethylenimine for improved lung gene transfer, Biochem. Biophys. Res. Commun. 375 (2008) 378-383.
124. W.J.W. Kollen, P. Midoux, P. Erbacher, A. Yip, A.C. Roche, M. Monsigny, M.C. Glick, T.F. Scanlin, Gluconoylated and glycosylated polylysines as vectors for gene transfer into cystic fibrosis airway epithelial cells, Hum. Gene Ther. 7 (1996) 1577-1586.
125. M. Elfinger, C. Maucksch, C. Rudolph, Characterization of lactoferrin as a targeting ligand for nonviral gene delivery to airway epithelial cells, Biomaterials 28 (2007) 3448-3455.
126. S. Li, Y. Tan, E. Viroonchatapan, B.R. Pitt, L. Huang, Targeted gene delivery to pulmonary endothelium by anti-PECAM antibody, Am. J. Physiol. 278 (2000) L504-L511.
127. T. Ferkol, J.C. Perales, E. Eckman, C.S. Kaetzel, R.W. Hanson, P.B. Davis, Gene transfer into the airway epithelium of animals by targeting the polymeric immunoglobulin receptor, J. Clin. Invest. 95 (1995) 493-502.
128. A. Renigunta, G. Krasteva, P. Koenig, F. Rose,W. Klepetko, F. Grimminger,W. Seeger, J.Haenze,DNA transfer into human lung cells is improvedwith Tat-RGD peptide by caveoli-mediated endocytosis, Bioconjug. Chem. 17 (2006) 327-334.
129. D. Sheppard, Airway epithelial integrins: why so many? Am. J. Respir. Cell Mol. Biol. 19 (1998) 349-351.
130. J. Xia, A. Martinez, H. Daniell, S. Ebert, Evaluation of biolistic gene transfer methods in vivo using non-invasive bioluminescent imaging techniques, BMC Biotechnol. 11 (2011) 62.
131. C.L. Tseng, S.Y.H. Wu, W.H. Wang, C.L. Peng, F.H. Lin, C.C. Lin, T.H. Young, M.J. Shieh, Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer, Biomaterials 29 (2008) 3014-3022.
132. O.M. Merkel, D. Librizzi, A. Pfestroff, T. Schurrat, M. Behe, T. Kissel, In vivo SPECT and real-time gamma camera imaging of biodistribution and pharmacokinetics of siRNA delivery using an optimized radiolabeling and purification procedure, Bioconjug. Chem. 20 (2009) 174-182.
133. C. Fang, M. Zhang, Nanoparticle-based theragnostics: integrating diagnostic and therapeutic potentials in nanomedicine, J. Control. Release 146 (2010) 2-5.
134. E.J.R. van Beek, J.M. Wild, H.U. Kauczor, W. Schreiber, J.P. Mugler III, E.E. de Lange, Functional MRI of the lung using hyperpolarized 3-helium gas, J. Magn. Reson. Imaging 20 (2004) 540-554.
135. P. Dames, B. Gleich, A. Flemmer, K. Hajek, N. Seidl, F. Wiekhorst, D. Eberbeck, I. Bittmann, C. Bergemann, T. Weyh, L. Trahms, J. Rosenecker, C. Rudolph, Targeted delivery of magnetic aerosol droplets to the lung, Nat. Nanotechnol. 2 (2007) 495-499.
136. M. Beck-Broichsitter, T. Schmehl, T. Gessler,W. Seeger, T. Kissel, Development of a biodegradable nanoparticle platform for sildenafil: Formulation optimization by factorial design analysis combined with application of charge-modified branched polyesters, J. Control. Release (2011), doi:10.1016/j.jconrel.2011.1009.1058.
137. A. Fischer, J. Stegemann, G. Scheuch, R. Siekmeier, Novel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials, Eur. J. Med. Res. 14 (2009) 71-77.
138. J. Denyer, T. Dyche, The Adaptive Aerosol Delivery (AAD) technology: past, present, and future, J. Aerosol Med. 23 (2010) S1-S10.
139. T. Gessler, W. Seeger, T. Schmehl, The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension, Ther. Adv. Respir. Dis. 5 (2011) 195-206.
140. M. Griese, D. Reinhardt, Smaller sized particles are preferentially taken up by alveolar type II pneumocytes, J. Drug Target. 5 (1998) 471-479.
141. C. Jaafar-Maalej, V. Andrieu, A. Elaissari, H. Fessi, Assessment methods of inhaled aerosols: technical aspects and applications, Expert Opin. Drug Deliv. 6 (2009) 941-959.